Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Inflammation Induced by Platelet-Activating Viperid Snake Venoms: Perspectives on Thromboinflammation.

Teixeira C, Fernandes CM, Leiguez E, Chudzinski-Tavassi AM.

Front Immunol. 2019 Sep 4;10:2082. doi: 10.3389/fimmu.2019.02082. eCollection 2019. Review.

2.

Proteomic informed by transcriptomic for salivary glands components of the camel tick Hyalomma dromedarii.

Bensaoud C, Aounallah H, Sciani JM, Faria F, Chudzinski-Tavassi AM, Bouattour A, M'ghirbi Y.

BMC Genomics. 2019 Aug 27;20(1):675. doi: 10.1186/s12864-019-6042-1.

3.

New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X.

Pavon LF, Capper D, Sibov TT, de Toledo SRC, Thomale UW, de Souza JG, Cabral FR, Berra CM, Silva da Costa MD, Mendonça Niçacio J, Dastoli PA, de Oliveira DM, Malheiros SMF, da Cruz EF, Malheiros JM, de Oliveira SM, Silva NS, Petrilli AS, Cappellano AM, Brunialti MC, Salomão R, de Paiva Neto MA, Chudzinski-Tavassi AM, Cavalheiro S.

Sci Rep. 2019 Jul 10;9(1):9973. doi: 10.1038/s41598-019-45799-4.

4.

Corrigendum to "Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro" [Biomed. Pharmacother. 66 (2012) 64-69].

Akagi EM, de Sá Júnior PL, Simons SM, Bellini MH, Barreto SA, Chudzinski-Tavassi AM.

Biomed Pharmacother. 2019 Oct;118:109108. doi: 10.1016/j.biopha.2019.109108. Epub 2019 Jun 22. No abstract available.

5.

Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity.

Maria DA, Will SEAL, Bosch RV, Souza JG, Sciani JM, Goldfeder MB, Rondon GG, Chudzinski-Tavassi AM.

Toxicol Rep. 2018 Dec 1;6:51-63. doi: 10.1016/j.toxrep.2018.11.014. eCollection 2019.

6.

Tropism of mesenchymal stem cell toward CD133+ stem cell of glioblastoma in vitro and promote tumor proliferation in vivo.

Pavon LF, Sibov TT, de Souza AV, da Cruz EF, Malheiros SMF, Cabral FR, de Souza JG, Boufleur P, de Oliveira DM, de Toledo SRC, Marti LC, Malheiros JM, Paiva FF, Tannús A, de Oliveira SM, Chudzinski-Tavassi AM, de Paiva Neto MA, Cavalheiro S.

Stem Cell Res Ther. 2018 Nov 9;9(1):310. doi: 10.1186/s13287-018-1049-0.

7.

Neuroprotective effect of rLosac on supplement-deprived mouse cultured cortical neurons involves maintenance of monocarboxylate transporter MCT2 protein levels.

Alvarez-Flores MP, Hébert A, Gouelle C, Geller S, Chudzinski-Tavassi AM, Pellerin L.

J Neurochem. 2019 Jan;148(1):80-96. doi: 10.1111/jnc.14617. Epub 2018 Dec 3.

8.

Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells.

Schmidt MCB, Morais KLP, Almeida MES, Iqbal A, Goldfeder MB, Chudzinski-Tavassi AM.

Cell Adh Migr. 2018 Sep 25:1-10. doi: 10.1080/19336918.2018.1516982. [Epub ahead of print]

PMID:
30238848
9.

Biodistribution and Pharmacokinetics of Amblyomin-X, a Novel Antitumour Protein Drug in Healthy Mice.

Boufleur P, Sciani JM, Goldfeder M, Faria F, Branco V, Chudzinski-Tavassi AM.

Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):111-120. doi: 10.1007/s13318-018-0500-z.

PMID:
30132264
10.

A Combined Computer-Aided Approach to Drive the Identification of Potential Epitopes in Protein Therapeutics.

Galvão da Silva BAV, Chudzinski-Tavassi AM, Pasqualoto KFM.

J Pharm Pharm Sci. 2018;21(1):268-285. doi: 10.18433/jpps29800.

11.

De novo assembly and annotation of Hyalomma dromedarii tick (Acari: Ixodidae) sialotranscriptome with regard to gender differences in gene expression.

Bensaoud C, Nishiyama MY Jr, Ben Hamda C, Lichtenstein F, Castro de Oliveira U, Faria F, Loiola Meirelles Junqueira-de-Azevedo I, Ghedira K, Bouattour A, M'Ghirbi Y, Chudzinski-Tavassi AM.

Parasit Vectors. 2018 May 24;11(1):314. doi: 10.1186/s13071-018-2874-9.

12.

Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology.

Pavon LF, Sibov TT, Caminada de Toledo SR, Mara de Oliveira D, Cabral FR, Gabriel de Souza J, Boufleur P, Marti LC, Malheiros JM, Ferreira da Cruz E, Paiva FF, Malheiros SMF, de Paiva Neto MA, Tannús A, Mascarenhas de Oliveira S, Silva NS, Cappellano AM, Petrilli AS, Chudzinski-Tavassi AM, Cavalheiro S.

Oncotarget. 2018 Apr 24;9(31):21731-21743. doi: 10.18632/oncotarget.24932. eCollection 2018 Apr 24.

13.

Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin.

Iqbal A, Goldfeder MB, Marques-Porto R, Asif H, Souza JG, Faria F, Chudzinski-Tavassi AM.

Sci Rep. 2017 May 3;7(1):1431. doi: 10.1038/s41598-017-01486-w.

14.

Exploring the in vivo wound healing effects of a recombinant hemolin from the caterpillar Lonomia obliqua.

Sato AC, Bosch RV, Will SE, Alvarez-Flores MP, Goldfeder MB, Pasqualoto KF, da Silva BA, de Andrade SA, Chudzinski-Tavassi AM.

J Venom Anim Toxins Incl Trop Dis. 2016 Dec 21;22:36. doi: 10.1186/s40409-016-0093-4. eCollection 2016.

15.

Mesenchymal stem cell-like properties of CD133+ glioblastoma initiating cells.

Pavon LF, Sibov TT, de Oliveira DM, Marti LC, Cabral FR, de Souza JG, Boufleur P, Malheiros SM, de Paiva Neto MA, da Cruz EF, Chudzinski-Tavassi AM, Cavalheiro S.

Oncotarget. 2016 Jun 28;7(26):40546-40557. doi: 10.18632/oncotarget.9658.

16.

Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.

de Souza JG, Morais KL, Anglés-Cano E, Boufleur P, de Mello ES, Maria DA, Origassa CS, de Campos Zampolli H, Câmara NO, Berra CM, Bosch RV, Chudzinski-Tavassi AM.

Oncotarget. 2016 Sep 20;7(38):62255-62266. doi: 10.18632/oncotarget.11555.

17.

Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.

Branco VG, Iqbal A, Alvarez-Flores MP, Sciani JM, de Andrade SA, Iwai LK, Serrano SM, Chudzinski-Tavassi AM.

Biochim Biophys Acta. 2016 Oct;1864(10):1428-35. doi: 10.1016/j.bbapap.2016.07.011. Epub 2016 Jul 30.

PMID:
27479486
18.

Hemolin triggers cell survival on fibroblasts in response to serum deprivation by inhibition of apoptosis.

Bosch RV, Alvarez-Flores MP, Maria DA, Chudzinski-Tavassi AM.

Biomed Pharmacother. 2016 Aug;82:537-46. doi: 10.1016/j.biopha.2016.05.043. Epub 2016 Jun 6.

PMID:
27470394
19.

Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.

Morais KL, Pacheco MT, Berra CM, Bosch RV, Sciani JM, Chammas R, de Freitas Saito R, Iqbal A, Chudzinski-Tavassi AM.

Mol Cell Biochem. 2016 Apr;415(1-2):119-31. doi: 10.1007/s11010-016-2683-4. Epub 2016 Mar 25.

20.

Harnessing the knowledge of animal toxins to generate drugs.

Zambelli VO, Pasqualoto KF, Picolo G, Chudzinski-Tavassi AM, Cury Y.

Pharmacol Res. 2016 Oct;112:30-36. doi: 10.1016/j.phrs.2016.01.009. Epub 2016 Jan 27. Review.

PMID:
26826284
21.

Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates.

Chudzinski-Tavassi AM, Morais KL, Pacheco MT, Pasqualoto KF, de Souza JG.

Biomed Pharmacother. 2016 Feb;77:14-9. doi: 10.1016/j.biopha.2015.11.003. Epub 2015 Dec 3. Review.

PMID:
26796259
22.

Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.

Pacheco MT, Morais KL, Berra CM, Demasi M, Sciani JM, Branco VG, Bosch RV, Iqbal A, Chudzinski-Tavassi AM.

Exp Cell Res. 2016 Jan 15;340(2):248-58. doi: 10.1016/j.yexcr.2015.12.016. Epub 2015 Dec 31.

PMID:
26748183
23.

Transcripts involved in hemostasis: Exploring salivary complexes from Haementeria vizottoi leeches through transcriptomics, phylogenetic studies and structural features.

Amorim AM, de Oliveira UC, Faria F, Pasqualoto KF, Junqueira-de-Azevedo Ide L, Chudzinski-Tavassi AM.

Toxicon. 2015 Nov;106:20-9. doi: 10.1016/j.toxicon.2015.09.002. Epub 2015 Sep 10.

PMID:
26363292
24.

Post-transcriptional control of Amblyomin-X on secretion of vascular endothelial growth factor and expression of adhesion molecules in endothelial cells.

Drewes CC, Dias RY, Branco VG, Cavalcante MF, Souza JG, Abdalla DS, Chudzinski-Tavassi AM, Farsky SH.

Toxicon. 2015 Jul;101:1-10. doi: 10.1016/j.toxicon.2015.04.002. Epub 2015 Apr 22.

25.

Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.

Pacheco MT, Berra CM, Morais KL, Sciani JM, Branco VG, Bosch RV, Chudzinski-Tavassi AM.

PLoS One. 2014 Dec 5;9(12):e111907. doi: 10.1371/journal.pone.0111907. eCollection 2014.

26.

Cytotoxic activity and degradation patterns of structural proteins by corneal isolates of Acanthamoeba spp.

Sant'ana VP, Carrijo-Carvalho LC, Foronda AS, Chudzinski-Tavassi AM, de Freitas D, de Carvalho FR.

Graefes Arch Clin Exp Ophthalmol. 2015 Jan;253(1):65-75. doi: 10.1007/s00417-014-2783-3. Epub 2014 Aug 27.

PMID:
25161076
27.

Structural findings and molecular modeling approach of a TFPI-like inhibitor.

Pasqualoto KF, Balan A, Barreto SA, Simons SM, Chudzinski-Tavassi AM.

Protein Pept Lett. 2014 May;21(5):452-7.

PMID:
24330085
28.

Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity.

Mafra CS, Carrijo-Carvalho LC, Chudzinski-Tavassi AM, Taguchi FM, Foronda AS, Carvalho FR, de Freitas D.

Invest Ophthalmol Vis Sci. 2013 Sep 27;54(9):6363-72. doi: 10.1167/iovs.13-11990.

PMID:
23900604
29.

Interaction of Leptospira interrogans with human proteolytic systems enhances dissemination through endothelial cells and protease levels.

Vieira ML, Alvarez-Flores MP, Kirchgatter K, Romero EC, Alves IJ, de Morais ZM, Vasconcellos SA, Chudzinski-Tavassi AM, Nascimento AL.

Infect Immun. 2013 May;81(5):1764-74. doi: 10.1128/IAI.00020-13. Epub 2013 Mar 11.

30.

Rational development of novel leads from animal secretion based on coagulation and cell targets: 1. In silico analysis to explore a peptide derivative as lipocalins' signature.

Mesquita Pasqualoto KF, Carrijo-Carvalho LC, Chudzinski-Tavassi AM.

Toxicon. 2013 Jul;69:200-10. doi: 10.1016/j.toxicon.2013.02.004. Epub 2013 Feb 20.

31.

A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis.

Ventura JS, Faria F, Batista IF, Simons SM, Oliveira DG, Morais KL, Chudzinski-Tavassi AM.

Biomed Pharmacother. 2013 Apr;67(3):192-6. doi: 10.1016/j.biopha.2012.11.009. Epub 2012 Dec 28.

PMID:
23433900
32.

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.

Maria DA, de Souza JG, Morais KL, Berra CM, Zampolli Hde C, Demasi M, Simons SM, de Freitas Saito R, Chammas R, Chudzinski-Tavassi AM.

Invest New Drugs. 2013 Jun;31(3):493-505. doi: 10.1007/s10637-012-9871-1. Epub 2012 Sep 14.

33.

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.

Seguin F, Carvalho MA, Bastos DC, Agostini M, Zecchin KG, Alvarez-Flores MP, Chudzinski-Tavassi AM, Coletta RD, Graner E.

Br J Cancer. 2012 Sep 4;107(6):977-87. doi: 10.1038/bjc.2012.355. Epub 2012 Aug 14.

34.

Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.

Oliveira DG, Alvarez-Flores MP, Lopes AR, Chudzinski-Tavassi AM.

Thromb Haemost. 2012 Sep;108(3):570-8. doi: 10.1160/TH12-04-0235. Epub 2012 Jul 10.

PMID:
22782262
35.

A lipocalin-derived Peptide modulating fibroblasts and extracellular matrix proteins.

Carrijo-Carvalho LC, Maria DA, Ventura JS, Morais KL, Melo RL, Rodrigues CJ, Chudzinski-Tavassi AM.

J Toxicol. 2012;2012:325250. doi: 10.1155/2012/325250. Epub 2012 Apr 26.

36.

Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation.

Andrade SA, Carrijo-Carvalho LC, Peceguini LA, Wlian L, Sato AC, Luchiari C, Silva ED, Maffei FH, Chudzinski-Tavassi AM.

Braz J Med Biol Res. 2012 Oct;45(10):929-34. Epub 2012 Jun 28.

37.

Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis.

Drewes CC, Dias RY, Hebeda CB, Simons SM, Barreto SA, Ferreira JM Jr, Chudzinski-Tavassi AM, Farsky SH.

Toxicon. 2012 Sep 1;60(3):333-40. doi: 10.1016/j.toxicon.2012.04.349. Epub 2012 May 7.

38.

Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro".

Akagi EM, Júnior PL, Simons SM, Bellini MH, Barreto SA, Chudzinski-Tavassi AM.

Biomed Pharmacother. 2012 Feb;66(1):64-9. doi: 10.1016/j.biopha.2011.11.015. Epub 2012 Jan 5. Erratum in: Biomed Pharmacother. 2019 Oct;118:109108.

PMID:
22281290
39.

The action of Amblyomma cajennense tick saliva in compounds of the hemostatic system and cytotoxicity in tumor cell lines.

Simons SM, Júnior PL, Faria F, Batista IF, Barros-Battesti DM, Labruna MB, Chudzinski-Tavassi AM.

Biomed Pharmacother. 2011 Sep;65(6):443-50. doi: 10.1016/j.biopha.2011.04.030. Epub 2011 Jun 12.

PMID:
21723081
40.

Losac, the first hemolin that exhibits procogulant activity through selective factor X proteolytic activation.

Alvarez-Flores MP, Furlin D, Ramos OH, Balan A, Konno K, Chudzinski-Tavassi AM.

J Biol Chem. 2011 Mar 4;286(9):6918-28. doi: 10.1074/jbc.M110.167718. Epub 2010 Dec 22.

41.

New insight into the mechanism of Lonomia obliqua envenoming: toxin involvement and molecular approach.

Alvarez Flores MP, Zannin M, Chudzinski-Tavassi AM.

Pathophysiol Haemost Thromb. 2010;37(1):1-16. doi: 10.1159/000320067. Epub 2010 Aug 14. Review.

PMID:
20714126
42.

A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system.

Chudzinski-Tavassi AM, De-Sá-Júnior PL, Simons SM, Maria DA, de Souza Ventura J, Batista IF, Faria F, Durães E, Reis EM, Demasi M.

Toxicon. 2010 Dec 15;56(7):1145-54. doi: 10.1016/j.toxicon.2010.04.019. Epub 2010 May 31.

PMID:
20570593
43.

A lipocalin sequence signature modulates cell survival.

Chudzinski-Tavassi AM, Carrijo-Carvalho LC, Waismam K, Farsky SH, Ramos OH, Reis CV.

FEBS Lett. 2010 Jul 2;584(13):2896-900. doi: 10.1016/j.febslet.2010.05.008. Epub 2010 May 13.

44.

Serine-like proteolytic enzymes correlated with differential pathogenicity in patients with acute Acanthamoeba keratitis.

de Souza Carvalho FR, Carrijo-Carvalho LC, Chudzinski-Tavassi AM, Foronda AS, de Freitas D.

Clin Microbiol Infect. 2011 Apr;17(4):603-9. doi: 10.1111/j.1469-0691.2010.03252.x.

45.

Immobilized kidney 28-kDa endostatin-related (KES28kDa) fragment promotes endothelial cell survival.

Bellini MH, Malpighi TF, Calvo FB, Miranda AR, Spencer PJ, Cichy MC, Simons SM, Chudzinski Tavassi AM, Fagundes dos Santos M, Junqueira Rodrigues C, Schor N.

Am J Nephrol. 2010;31(3):255-61. doi: 10.1159/000278756. Epub 2010 Jan 25.

PMID:
20110665
46.

A new Factor Xa inhibitor from Amblyomma cajennense with a unique domain composition.

Batista IF, Ramos OH, Ventura JS, Junqueira-de-Azevedo IL, Ho PL, Chudzinski-Tavassi AM.

Arch Biochem Biophys. 2010 Jan 15;493(2):151-6. doi: 10.1016/j.abb.2009.10.009. Epub 2009 Oct 22.

PMID:
19853573
47.

Lopap: a non-inflammatory and cytoprotective molecule in neutrophils and endothelial cells.

Waismam K, Chudzinski-Tavassi AM, Carrijo-Carvalho LC, Pacheco MT, Farsky SH.

Toxicon. 2009 May;53(6):652-9. doi: 10.1016/j.toxicon.2009.01.031.

PMID:
19673080
48.

Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.

Ferreira MA, do Nascimento NR, de Sousa CM, Pessoa OD, de Lemos TL, Ventura JS, Schattner M, Chudzinski-Tavassi AM.

Br J Pharmacol. 2008 Jul;154(6):1216-24. doi: 10.1038/bjp.2008.199. Epub 2008 Jun 2.

49.

Immunochemical and proteomic technologies as tools for unravelling toxins involved in envenoming by accidental contact with Lonomia obliqua caterpillars.

Ricci-Silva ME, Valente RH, León IR, Tambourgi DV, Ramos OH, Perales J, Chudzinski-Tavassi AM.

Toxicon. 2008 May;51(6):1017-28. doi: 10.1016/j.toxicon.2008.01.013. Epub 2008 Feb 3.

PMID:
18342903
50.

Expressed sequence tags (ESTs) from the salivary glands of the tick Amblyomma cajennense (Acari: Ixodidae).

Batista IF, Chudzinski-Tavassi AM, Faria F, Simons SM, Barros-Batestti DM, Labruna MB, Leão LI, Ho PL, Junqueira-de-Azevedo IL.

Toxicon. 2008 Apr;51(5):823-34. doi: 10.1016/j.toxicon.2007.12.011. Epub 2007 Dec 17.

PMID:
18243270

Supplemental Content

Loading ...
Support Center